Literature DB >> 12039432

Linking clinical variables to health-related quality of life in Parkinson's disease.

Elizabeth A Chrischilles1, Linda M Rubenstein, Margaret D Voelker, Robert B Wallace, Robert L Rodnitzky.   

Abstract

OBJECTIVE: Identify the point-in-time relationship between Parkinson's disease (PD) signs and symptoms and measures of health-related quality of life (HRQL).
BACKGROUND: Clinical measures used in PD assessments traditionally emphasize physical signs and symptoms. We hypothesized that these measures would be strongly associated with the physical function dimensions of HRQL that reflect mental symptoms. DESIGN/
METHODS: A cross-sectional study of 193 neurology clinic PD patients employed self-administered in-clinic and take-home questionnaires and in-person clinical examinations and interviews.
RESULTS: The variance explained by PD physical signs and symptoms was substantial for physical function, but only modest for all other HRQL dimensions. Mental symptoms explained a larger proportion of variance than physical symptoms for 12 of the 14 HRQL measures.
CONCLUSION: PD patients' well-being, general health perceptions, health satisfaction and overall HRQL are strongly influenced by mental health symptoms and more weakly influenced by physical symptoms. Clinical evaluation of PD patients should include mental health and self-reported HRQL assessment.

Entities:  

Mesh:

Year:  2002        PMID: 12039432     DOI: 10.1016/s1353-8020(01)00044-x

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  16 in total

1.  Putting Wilson and Cleary to the test: analysis of a HRQOL conceptual model using structural equation modeling.

Authors:  Karen H Sousa; Oi-Man Kwok
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

2.  Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson's disease.

Authors:  Sabrina Schröder; Peter Martus; Per Odin; Marion Schaefer
Journal:  Int J Clin Pharm       Date:  2012-07-19

3.  Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.

Authors:  E M Cheng; S Tonn; R Swain-Eng; S A Factor; W J Weiner; C T Bever
Journal:  Neurology       Date:  2010-11-30       Impact factor: 9.910

4.  Understanding the relationships between health outcomes in generalized anxiety disorder clinical trials.

Authors:  Kathleen W Wyrwich; Neesha Harnam; Julie C Locklear; Henrik Svedsäter; Dennis A Revicki
Journal:  Qual Life Res       Date:  2010-08-31       Impact factor: 4.147

5.  Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease.

Authors:  Randolph Stephenson; David Houghton; Sri Sundarararjan; Richard L Doty; Matthew Stern; Sharon X Xie; Andrew Siderowf
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

6.  A comprehensive model of health-related quality of life in Parkinson's disease.

Authors:  M Visser; S M van Rooden; D Verbaan; J Marinus; A M Stiggelbout; J J van Hilten
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

7.  Health-related quality of life in Parkinson disease: correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale (UPDRS) in U.S. male veterans.

Authors:  Galit Kleiner-Fisman; Matthew B Stern; David N Fisman
Journal:  Health Qual Life Outcomes       Date:  2010-08-30       Impact factor: 3.186

Review 8.  Treatment of depression in Parkinson's disease.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

Review 9.  CBT for the treatment of depression in Parkinson's disease: a promising nonpharmacological approach.

Authors:  Roseanne DeFronzo Dobkin; Matthew Menza; Karina L Bienfait
Journal:  Expert Rev Neurother       Date:  2008-01       Impact factor: 4.618

10.  Independent contributors to overall quality of life in people with advanced cancer.

Authors:  A M Rodríguez; N E Mayo; B Gagnon
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.